Image

Global Autoimmune Gastrointestinal Dysmotility Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

Global Autoimmune Gastrointestinal Dysmotility Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Apr 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Autoimmune Gastrointestinal Dysmotility Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 28.00 Billion
Diagram Market Size (Forecast Year) USD 128.54 Billion
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Autoimmune Gastrointestinal Dysmotility Market, By Treatment (Plasma Exchange, Medications, Immunotherapy), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Others) – Industry Trends and Forecast to 2030.

Autoimmune Gastrointestinal Dysmotility Market Analysis and Size

The autoimmune gastrointestinal dysmotility market is experiencing significant growth, driven by increasing awareness about autoimmune diseases, advancements in diagnostic techniques, and the rising prevalence of gastrointestinal disorders. The market is witnessing a surge in research and development activities aimed at developing novel therapies and improving existing treatment options.  With the increasing focus on personalized medicine and the development of targeted therapies, the  market is expected to continue expanding in the coming years.

Data Bridge Market Research analyzes that the global autoimmune gastrointestinal dysmotility market was valued at USD 28.00 billion in 2022 and is expected to reach USD 128.54 billion by 2030, registering a CAGR of 18.7% during the forecast period of 2023-2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2024 to 2031

Base Year

2023

Historic Years

2022 (Customizable to 2016-2021)

Quantitative Units

Revenue in USD Billion, Pricing in USD

Segments Covered

By Treatment (Plasma Exchange, Medications, Immunotherapy), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Others)

Countries Covered

U.S., Canada, Mexico, Germany, Sweden, Poland, Denmark, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa , Brazil, Argentina, Rest of South America

Market Players Covered

YCELLBIO MEDICAL (South Korea), Zimmer Biomet (U.S.), Stryker (U.S.), ROCKY MOUNTAIN BIOLOGICALS (U.S.), Regen Lab SA (Switzerland), TERUMO BCT, INC. (U.S.), GLOFINN (Finland), ExaTech Inc. (U.S.), EmCyte Corporation (U.S.), ThermoGenesis Holding, Inc. (U.S.), Octapharma Brasil Ltda (Brazil), Dr PRP USA LLC (U.S.), Isto Biologics (U.S.), Arthrex, Inc. (U.S.), Terumo Corporation (Japan), Cascade Medical. (U.S.), Grifols, S.A. (Spain)

Market Opportunities

  • Telemedicine and Remote Monitoring
  • Personalized Medicine

Market Definition

Autoimmune gastrointestinal dysmotility (AGID) refers to a condition in which the immune system mistakenly targets and attacks the nerves or muscles of the gastrointestinal (GI) tract, leading to disruptions in the normal movement and function of the digestive system. The GI tract includes organs such as the esophagus, stomach, small intestine, and large intestine, and their coordinated movement is essential for the proper digestion and absorption of nutrients.

Global Autoimmune Gastrointestinal Dysmotility Market Dynamics

Drivers

  • Immunological Factors

In autoimmune disorders, including AGID, the immune system mistakenly targets and attacks the nerves or muscles in the digestive tract, leading to impaired motility. As researchers gain a better understanding of the immunological mechanisms underlying autoimmune gastrointestinal dysmotility, they can develop targeted therapies that specifically modulate the immune response. This has led to the development of biologics and other immunomodulatory agents that show promise in treating autoimmune gastrointestinal dysmotility by suppressing the autoimmune response and reducing inflammation in the gastrointestinal tract. Immunological factors play a crucial role in driving the market.

  • Environmental Triggers

Environmental factors such as diet, infections, and exposure to toxins can trigger or exacerbate autoimmune responses in susceptible individuals. For example, certain dietary components have been linked to increased gut permeability and inflammation, which can contribute to autoimmune gastrointestinal dysmotility. Understanding these environmental triggers can help in developing preventive strategies and identifying high-risk individuals, thereby driving the demand for diagnostic tests and therapies for autoimmune gastrointestinal dysmotility.

Opportunities

  • Personalized Medicine

As per the understanding of the genetic and molecular factors influencing autoimmune disorders deepens, there is an opportunity to develop personalized treatment approaches. Personalizing therapies based on an individual's genetic makeup, immunological profile, and other factors could lead to more effective and targeted interventions.

  • Telemedicine and Remote Monitoring

Advances in telemedicine and remote monitoring technologies can improve access to healthcare for individuals with AGID. Remote monitoring of symptoms and virtual consultations can enhance patient care, particularly for those who may face challenges with physical mobility., this creates new opportunities for the market.

Restraints/Challenges

  • Complexity of Diagnosing AGID

Diagnosing AGID can be challenging due to the diversity of symptoms and the lack of specific diagnostic markers. The condition may mimic other gastrointestinal disorders, leading to misdiagnosis or delayed diagnosis. As a result, individuals with AGID may experience prolonged periods of uncertainty and frustration. There is currently no cure for AGID, and treatment options are often aimed at managing symptoms and modulating the immune response. Immunosuppressive medications may be used, but they can have side effects and may not be universally effective, which is a major challenge for the market.

This autoimmune gastrointestinal dysmotility market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the autoimmune gastrointestinal dysmotility market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

  • In April 2022, TheraCell Inc., a leading allograft solution company, today announced that Isto Biologics have acquired it, a leader in surgical-based, orthobiologic regeneration technologies and cell-based therapies
  • In October 2020, Evoke Pharma, Inc. and EVERSANA announced the commercial launch of Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis

Global Autoimmune Gastrointestinal Dysmotility Market Scope

The autoimmune gastrointestinal dysmotility market is segmented on the basis of product type, compound, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

  • Plasma Exchange
  • Medications
  • Immunotherapy

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others

Global Autoimmune Gastrointestinal Dysmotility Market Regional Analysis/Insights

The autoimmune gastrointestinal dysmotility market is analyzed and market size insights and trends are provided by country, product type, compound, application and end-user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, Sweden, Poland, Denmark, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa , Brazil, Argentina and rest of South America.

North America is expected to dominate and be the highest growing region in the market due to it increasing rapidly over the past few years due to the expansion of the major players' production capacities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The autoimmune gastrointestinal dysmotility market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for autoimmune gastrointestinal dysmotility market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the autoimmune gastrointestinal dysmotility market. The data is available for historic period 2010-2020.

Competitive Landscape and Global Autoimmune Gastrointestinal Dysmotility Market Share Analysis

The autoimmune gastrointestinal dysmotility market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to autoimmune gastrointestinal dysmotility market.

Some of the major players operating in the autoimmune gastrointestinal dysmotility market are:

  • YCELLBIO MEDICAL (South Korea)
  • Zimmer Biomet (U.S.)
  • Stryker (U.S.)
  • ROCKY MOUNTAIN BIOLOGICALS (U.S.)
  • Regen Lab SA (Switzerland)
  • TERUMO BCT, INC. (U.S.)
  • GLOFINN (Finland)
  • ExaTech Inc. (U.S.)
  • EmCyte Corporation (U.S.)
  • ThermoGenesis Holding, Inc. (U.S.)
  • Octapharma Brasil Ltda (Brazil)
  • Dr PRP USA LLC (U.S.)
  • Isto Biologics (U.S.)
  • Arthrex, Inc. (U.S.)
  • Terumo Corporation (Japan)
  • Cascade Medical. (U.S.)
  • Grifols, S.A. (Spain)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

Major companies in the autoimmune gastrointestinal dysmotility market are YCELLBIO MEDICAL (South Korea), Zimmer Biomet (U.S.), Stryker (U.S.), ROCKY MOUNTAIN BIOLOGICALS (U.S.), Regen Lab SA (Switzerland), TERUMO BCT, INC. (U.S.), GLOFINN (Finland), ExaTech Inc. (U.S.), EmCyte Corporation (U.S.), ThermoGenesis Holding, Inc. (U.S.), Octapharma Brasil Ltda (Brazil), Dr PRP USA LLC (U.S.), Isto Biologics (U.S.), Arthrex, Inc. (U.S.), Terumo Corporation (Japan), Cascade Medical. (U.S.), Grifols, S.A. (Spain).
Immunological Factors & Environmental Triggers such as diet, infections, and exposure to toxins are the growth drivers of the autoimmune gastrointestinal dysmotility market.
Product type, compound, application and end-user are the factors on which the autoimmune gastrointestinal dysmotility market research is based.
The autoimmune gastrointestinal dysmotility market size will be worth USD 128.54 billion by 2030.
The growth rate of the autoimmune gastrointestinal dysmotility market is 18.7%.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials